Vivacitas Chan Board Appointment

Vivacitas Oncology Appoints Mr. Heng Fai Chan
to the Board of Directors

Walnut Creek, CA – May 23rd, 2017 – Vivacitas Oncology Inc. (“Vivacitas”, or the
“Company”), a biopharmaceutical company focused on developing camptothecin-based
medications for cancer patients, announces the appointment of Mr. Heng Fai Chan to the
Company’s Board of Directors. Concurrently, Heng Fai Enterprises Pte Ltd., controlled by Mr.
Chan, made an investment into Vivacitas Oncology through the purchase of common stock. Mr.
Chan brings over 40 years of international business experience to the board of directors with an
exemplary track record of restructuring companies.

“Vivacitas represents a tremendous investment opportunity in the field of oncologic drug
development as the pipeline assets have progressed to a relatively late stage and are
differentiated from other camptothecins in their improved formulations and reduced side
effects,” said Mr. Chan. “Led by the Company’s scientific founder, the late Dr. Joseph
Rubinfeld, the acquisition of Rubitecan (Orathecin) in the fourth quarter of 2016 enhanced the
Company’s pipeline by adding a unique camptothecin-based formula that can be given orally.
Taken together with the pipeline drug AR-67, acquired from a public company in early 2016,
Vivacitas’ mid-to late- stage portfolio is positioned to fight a spectrum of cancers using
camptothecins, which have been known for decades to have chemotherapeutics effects in a
multitude of cancers. My immediate focus is to help the Company with its capital raising efforts
and strategic transactions as we bring new treatments forward for patients.”

Mr. Chan, based in Singapore, brings more than 40 years of operational experience; from
founding companies to restructuring others globally, his companies speak to his expertise. He
founded his first business while attending college in London during the late 1960’s. Interasia
Travel Limited grew to 14 offices with 300 employees prior to its sale to an established
Malaysian financial firm. Mr. Chan also acquires companies to focus on streamlining and
thereby accelerating growth; included in this list are American Pacific Bank, Skywest Airlines,
China Gas Holdings Limited, and SingXpress Land Limited. Mr. Chan is currently the Chief
Executive Officer of Singapore eDevelopment Limited (SGX: 40V) (“SED”).

About AR67
AR-67 is a third generation camptothecin, administered intravenously. In preclinical studies,
AR-67 showed improved pharmacokinetics and stability profiles as well as a significant increase
in potency, which comes from its increased lipophilicity. The dose-limiting toxicities have been
reduced in more than 80 patients who have been exposed to the drug. AR-67 has completed a
Phase 2 clinical study in Glioblastoma Multiforme and has recently received Orphan Drug
Designation in this indication. Planning for the next clinical trial is underway.

About Rubitecan/Orathecin:
Rubitecan, a second generation camptothecin, is the only oral medication in this drug class. The
program has garnered US FDA Orphan Drug Designation in two indications, pancreatic cancer
and pediatric HIV/AIDS as an anti-viral therapy, and has Fast Track Designation in pancreatic
cancer. Rubitecan has been evaluated in more than 1000 patients to date and has a well-
established safety profile. Rubitecan was originally developed by Supergen, Inc. to the point of
NDA submission. Vivacitas is reviewing the program and taking steps to reinitiate the
submission process for patients with pancreatic cancer.

About Mitozytrex:
Mitozytrex is a new version of the well-known generic drug, Mitomycin C (MMC), specially
formulated to overcome some of the key obstacles associated with MMC use as a cytotoxic
therapy. The program was acquired with Rubitecan in late 2016 and serves as a model validating
the reformulation technology originally developed by Supergen, Inc. The Company is evaluating
next steps to re-institute the previously approved NDA.

About Vivacitas Oncology:
Vivacitas Oncology, a privately held company, was co-founded by Dr. Joseph Rubinfeld in 2015
with the mission of bringing more effective and less toxic chemotherapies to market for the most
aggressive and intractable cancers. In 2016, the company acquired AR-67, a late-clinical Phase 2
stage camptothecin, and Rubitecan, a post-clinical Phase 3 stage camptothecin, with potentials in
Glioblastoma Multiforme and pancreatic cancer, respectively. Led by a highly-experienced team,
the Company also enjoys the counsel and support of a distinguished Medical Advisory Board
composed of internationally recognized oncologists, surgeons, and clinical researchers.

For further information please visit

Forward-Looking Statements

Certain statements, other than purely historical information, including estimates, projections,
statements relating to our business plans, objectives, and expected operating results, and the
assumptions upon which those statements are based, are forward-looking statements. These
forward-looking statements generally are identified by the words “believes,” “project,” “expects,”
“anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will
continue,” “will likely result,” and similar expressions. Forward-looking statements are based on
current expectations and assumptions that are subject to risks and uncertainties which may cause
actual results to differ materially from the forward-looking statements. Our ability to predict
results or the actual effect of future plans or strategies is inherently uncertain. Factors which
could have a material adverse effect on our operations and future prospects on a consolidated
basis include, but are not limited to: changes in economic conditions, legislative/regulatory
changes, availability of capital, interest rates, competition, and generally accepted accounting
principles. These risks and uncertainties should also be considered in evaluating forward-looking
statements and undue reliance should not be placed on such statements.